News & Events
ChemGenex Announces Convertible Note Issue and Welcomes Cephalon, Inc. as a Substantial Investor
22 / 10 / 2010
• Substantial Shareholders Sign Option Agreements with Subsidiary of Cephalon, Inc over 19.9% of ChemGenex Shares at A$0.70 per Share
ChemGenex Completes pre-NDA Meeting with U.S. FDA and Clarifies Timing for Second New Drug Application for OMAPROTM
06 / 10 / 2010
CoDa Therapeutics’ NEXAGON® Wound Healing Gel Named to Windhover’s “Top 10 HOT SPACE Projects to Watch”
17 / 09 / 2010
Sunshine Heart Announces First Minimally Invasive Thoracotomy Procedures Performed for the C-Pulse® Heart Assist System
31 / 08 / 2010
AIMEDICS secures funding for the commercialisation of its overnight hypoglycaemia monitor
27 / 08 / 2010
KaloBios, Seeking to Apply Antibodies Beyond Cancer, Sets Sight on Killing Deadly Lung Invader
17 / 08 / 2010
ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO:
13 / 07 / 2010
• Company will submit new NDA in CML patients who have failed multiple TKIs • Investor Teleconference to be held today - Wednesday 14th July 10.30am AEST /Tuesday 13th July 5.30
Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
13 / 07 / 2010
Women’s Sexual Health Research on Podium at 2010 Joint ICS/IUGA Meeting
UPTAKE MEDICAL COMPLETES SERIES B FINANCING ROUNDFOR $17.5 MILLION -Seattle, Wash. and Irvine, Calif., USA
07 / 07 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
29 / 06 / 2010
ASX Announcement First Minimally Invasive C-Pulse Procedure Performed at University of Louisville Sydney, Australia
15 / 06 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
25 / 05 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers - 69% Reduction in Venous Leg Ulcer Size in High-Dose Arm at 4 Weeks - 31% of Wounds Completely Healed in High-Dose Arm at 4 Weeks
Displaying records 76-100 of 372